Tyra Biosciences
TYRA
48 hedge funds and large institutions have $256M invested in Tyra Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
4% more funds holding
Funds holding: 46 → 48 (+2)
1.24% less ownership
Funds ownership: 86.84% → 85.6% (-1.2%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
34% less capital invested
Capital invested by funds: $387M → $256M (-$131M)
Top Buyers
Top Sellers
TYRA Hedge Fund Activity: Q2 2022 in Review
48 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q2 2022, worth a combined $256M — down 34% from $387M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TYRA positions and 3 closed out — a net gain of 3 holders — while 18 added to existing stakes and 16 trimmed.
The largest buyer was Fairmount Funds Management, adding an estimated $1.05M. The largest seller was Janus Henderson Group, cutting an estimated $1.57M.
- 48 institutional investors held Tyra Biosciences (TYRA) as of Q2 2022, up from 46 in Q1 2022.
- Funds reported $256M of Tyra Biosciences stock for Q2 2022, down 34% quarter-over-quarter.
- 6 funds opened new Tyra Biosciences positions in Q2 2022 and 3 closed out, a net change of +3 holders.
- The largest Tyra Biosciences buyer in Q2 2022 was Fairmount Funds Management, an estimated $1.05M added.
- The largest Tyra Biosciences seller in Q2 2022 was Janus Henderson Group, an estimated $1.57M sold.
Based on aggregated 13F filings for Q2 2022.